TGEN - Targeted Genetics Corporation Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : TGEN - Targeted Genetics Corporation

TGEN 8.230

+0.9%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Mike McFarland who wrote (206)	1/28/2000 9:14:00 PM
From: Mike McFarland	Read Replies (1) of 557

AMENDMENTS AND UPDATES... December 8-10, 1999 www4.od.nih.gov October 15, 1999 9409-083 Zeitlin A Phase I Study of an Adeno-Associated Virus-CFTR Gene Vector in Adult CF Patients with Mild Lung Disease Amendments: 1) One new site/investigator is added. Terence R. Flotte, M.D.; University of Florida; Gainesville, Florida. 2) Large number of amendments have been made. Significant changes are that, based upon rabbit toxicological data, the maximum dose will now be 1x10^9 RU (replication units) of tgAAVCF administered to the lung. In addition, the lower age has been changed from 18 to 15 years old.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next